Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.
The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.
It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers.
The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H.
Lee Moffitt Cancer Center; The University of TexasM. D.
Anderson Cancer Center; CellectisS. A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH.
The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017.
Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -0.34 Increased by +27.66% | -0.35 Increased by +2.86% |
| May 9, 24 | -0.42 Increased by +16.00% | -0.42 |
| Feb 28, 24 | -0.45 Increased by +29.69% | -0.43 Decreased by -4.65% |
| Nov 7, 23 | -0.46 Increased by +26.98% | -0.45 Decreased by -2.22% |
| Aug 8, 23 | -0.47 Increased by +25.40% | -0.80 Increased by +41.25% |
| May 9, 23 | -0.50 Increased by +13.79% | -0.74 Increased by +32.43% |
| Feb 28, 23 | -0.64 Decreased by -1.59% | -0.64 |
| Nov 3, 22 | -0.63 Decreased by -14.55% | -0.64 Increased by +1.56% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 58.55 M Increased by +12.39 K% | -83.54 M Increased by +26.56% | Decreased by -142.67% Increased by +99.41% |
| Jun 30, 24 | 31.11 M Increased by +12.97 K% | -97.10 M Increased by +8.85% | Decreased by -312.16% Increased by +99.30% |
| Mar 31, 24 | 715.00 K Increased by +N/A% | -112.98 M Decreased by -8.75% | Decreased by -15.80 K% Decreased by N/A% |
| Dec 31, 23 | 482.00 K Increased by +N/A% | -116.38 M Decreased by -14.23% | Decreased by -24.15 K% Decreased by N/A% |
| Sep 30, 23 | 469.00 K Increased by +N/A% | -113.76 M Decreased by -15.09% | Decreased by -24.26 K% Decreased by N/A% |
| Jun 30, 23 | 238.00 K Increased by +N/A% | -106.53 M Decreased by -7.64% | Decreased by -44.76 K% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -103.88 M Decreased by -13.53% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -101.89 M Decreased by -2.57% | Decreased by N/A% Decreased by N/A% |